Ask AI
ProCE Banner Activity

CLL Updates: Experts Offer Guidance on the Latest Evidence From ASH 2025 and Address Commonly Asked Questions

Clinical Thought

In this commentary, experts on CLL provide insight into new evidence for the management of treatment-naive CLL based on key studies presented at the 2025 American Society for Hematology annual meeting. Then they address commonly asked questions posed by a healthcare professional audience during a recent live webinar. 

Released: December 31, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Target Audience

This activity is intended for hematologists, medical oncologists, and other healthcare professionals who care for patients with chronic lymphocytic leukemia / small lymphocytic lymphoma. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Incorporate CLL/SLL molecular pathogenesis of available BTK inhibitors, as well as mechanisms of resistance and tolerance of prior therapy when developing individualized treatment approaches for patients

  • Select optimal guideline-recommended BTK inhibitor treatments for patients with CLL/SLL across the disease spectrum, based on current evidence, guidelines, expert guidance, and patient goals and preferences

  • Integrate current evidence on evolving BTK inhibitor approaches into treatment planning for patients with CLL/SLL across the disease spectrum

  • Identify and manage BTK inhibitor–associated adverse events in patients with CLL/SLL and educate them on when to call their care team

Disclosure

Primary Author

Sameh Gaballa, MD: consultant/advisor/speaker: AbbVie, Adaptive Biotechnologies, ADC Therapeutics, AstraZeneca, BeOne, Incyte, Ipsen, Lilly, Regeneron.

Nitin Jain, MD: advisor/honoraria: AbbVie, Adaptive, AstraZeneca, Autolus, BeOne, Bristol Myers Squibb, Cellectis, Genentech, Janssen, Kite/Gilead, Lilly, Novalgen, Nurix, Pharmacyclics, SERB Pharma; research: AbbVie, Adaptive, ADC Therapeutics, Ascentage, AstraZeneca, BeOne, Bioheng, Bristol Myers Squibb, Carna, Cellectis, Fate, Genentech, Kisoji, Kite/Gilead, Lilly, Mingsight, Newave, Novartis, Precision Biosciences, Pharmacyclics, Sana, Takeda, Triarm, Ubix.